

## THE NEW YORK BLOOD CENTER



310 East 67 Street, New York, N.Y. 10021 (212) 570-3000

May 8, 1985

Dr. Richard S. Lane  
Blood Products Laboratory  
Dagger Lane  
Elstree  
Hertfordshire WD6 3BX  
ENGLAND

Dear Dr. Lane:

The New York Blood Center has developed a new virus inactivation method which has been successfully applied to a variety of labile blood derivatives, reducing or eliminating their content of infectious virus with little or no effect on protein structure and activity.

The method has been shown to inactivate hepatitis B, hepatitis non-A, non-B, HTLV-III, and other lipid-enveloped viruses. The method is suitable for use in the production of antihemophilic factor concentrate, prothrombin complex concentrate, immune globulins, fibronectin as well as other biologicals derived from human sources.

The U.S. patent is expected to be issued shortly, and patents are pending or being issued in other countries as well.

We are prepared to license this virus inactivation technology to qualified organizations. If you are interested in the technology, please write or call. The telex number is 237 909 HEMO UR.

This general announcement is for registered producers of plasma derivatives. We wanted to be sure that you were aware of the availability of our process for license, even though your staff may have been previously informed of this by one of our senior scientists.

Sincerely,

GRO-C

James W. Holland  
Managing Director  
Blood Derivatives Program

JWH:ah